The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab
Status:
Terminated
Trial end date:
2019-03-20
Target enrollment:
Participant gender:
Summary
For patients with nonsquamous NSCLC and a good performance status (PS), pemetrexed and
cisplatin has been recommended for first-line NSCLC treatment. Recently, results from the
PARAMOUNT trial showed that patients with nonsquamous NSCLC who had a good PS and had not
progressed after completing four cycles of pemetrexed-cisplatin induction therapy benefitted
from pemetrexed continuation maintenance therapy. Furthermore, pemetrexed with bevacizumab
continuous maintenance might be better treatment option, considering the results from
AVAPEARL trial. Pemetrexed rechallenge has been reported to be effective in some patients.
Therefore, in order to investigate the safety and efficacy of pemetrexed rechallenge with
bevacizumab,we conducted this study.